Does Pacing the Frontier Hurt AI Lab Profits? Pharma Regulation Says No

bookwormengr · x · 2026-09-13

Pushing back on @tszzl's claim that "pacing the frontier" would asymmetrically compress frontier lab margins and amount to regulatory capture, bookwormengr cites pharma regulation: strict rules never dented incumbents' profits, since patients buy medicine at whatever cost — suggesting AI demand may be similarly inelastic under slower frontier pacing.

Original post →

More from Safety

Safety channel →